NV-AQARA
Aqara, a leading provider of smart home products, is thrilled to announce its participation in CES 2024. At the event, Aqara will showcase its latest innovations, including the new Border Router Plug and Smart Lock U300, as well as other advanced smart home solutions and prototypes at its booth in the Venetian Expo (#53513).
Aqara is an early advocate of the industry-unifying Matter standard and is committed to delivering seamless smart home experiences for users. The Border Router Plug and Smart Lock U300 will be Thread-capable, which will add to Aqara's growing number of native Matter products, making Aqara devices more interoperable. These two new products previewed at CES are expected to become available for order in the coming months.
Border Router Plug
The Aqara Border Router Plug represents an innovative advancement in smart plug and is among the first smart plugs announced to incorporate Thread Border Router capabilities. Equipped with Thread and dual-band Wi-Fi, this plug enables Matter controllers without Thread capability to manage Thread devices, allowing seamless integration of Thread devices into smart home systems without needing a new Matter controller.
This plug is energy-efficient, particularly in Thread-only mode, which reduces idle consumption while extending the mesh Thread network by routing the data packets. It is also energy-conscious, providing real-time and historical data on home energy consumption, enabling users to automate their electrical devices to reduce energy waste. Additionally, the Border Router Plug can sense the on/off status of the connected appliance and trigger Aqara Home automations accordingly. For example, users can have the curtains close automatically when the TV is on to eliminate potential sun glare.
The Aqara Border Router Plug utilizes an NXP® Semiconductors' secure wireless MCU. As part of the ongoing collaboration between Aqara and NXP Semiconductors, the Border Router Plug will also be featured in NXP's Smart Home Experience showcase during CES 2024, along with the NXP-powered Aqara Door and Window Sensor P2.
Smart Lock U300
The Aqara Smart Lock U300 is one of the first smart lever locks announced to feature Matter and Thread compatibility, and offers unprecedented interoperability with various smart home platforms. This versatility is coupled with an extended battery life of up to 8 months and enhanced local control, which improves responsiveness, privacy and security.
Designed for both indoor and outdoor use, the U300 replaces the traditional US lever or knob on single-bore doors and is ideal for including side entries, garage entries, home offices, basements and storage rooms. It enables a key-free lifestyle with multiple access options, including fingerprints, PIN codes, NFC, or voice assistants. Homeowners can control the lock remotely, grant temporary access to guests, and receive real-time notifications of who comes and goes - all from a smartphone.
Aqara Home App Update
At CES 2024, Aqara will also showcase Home Copilot, the new chatbot interface for the Aqara Home app, which is powered by Gen-AI. Home Copilot is designed to enhance user experiences by utilizing ambient intelligence, which helps convert real-time data and insights into actions. Ultimately, Home Copilot will be able to analyze the usage patterns in an Aqara home and proactively suggest customized automations. It will also understand natural language and configure automations per user requests. Users can automate their homes via simple voice and text instructions, which makes smart home even more intuitive and easy to use.
Initially, Home Copilot will enable Aqara Insights, a daily, weekly and monthly smart home reports for users, and provide tailored plans for energy-saving automation. It will support natural language queries for Aqara devices and automations and offer proactive assistance with device setup and troubleshooting. Home Copilot will also spearhead the AI-powered customer support interface for Aqara users in over 10 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108777203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release
Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 14:30:00 CEST | Press release
- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest population of people living with TDT in Europe- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformati
European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary18.9.2025 12:41:00 CEST | Press release
European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head of Structured Finance, before taking on advisory and leadership roles in the securitisation market. Markus Schaber, outgoing Executive Director of EDW Ltd., will remain with the company as Senior Advisor. He commented: “It has been a privilege to lead European DataWarehouse in the UK and contribute to the development of greater transparency in European securitisation markets. I am confident that Nigel’s deep industry knowledge and leadership will strengthen EDW Ltd.’s mission and ensure we continu
Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites18.9.2025 11:20:00 CEST | Press release
Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qualified, with Zycus placed in the Customers’ Choice quadrant — highlighting vendors rated above the market average for both Overall Experience and User Interest & Adoption. Recognition Backed by Customer Experience According to the report, Zycus achieved: 4.6 out of 5 Overall Rating, based on 67 peer reviews as of June 30, 2025. 95% willingness to recommend score – reflecting customer trust and satisfaction. Ratings across Product Capabilities, Sales Experience, Deployment, and Support, each above 4
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 11:00:00 CEST | Press release
Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom